Fact Sheet: Single-Payer In California Is Not The Answer

Fact Sheet: Single-Payer In California Is Not The Answer

Runaway Rx: SB 17 News Recap

Runaway Rx: SB 17 News Recap

CAHP Statement: $400 Billion Single-Payer Health Care Bill Passes Senate

The California State Senate today approved SB 562 (Lara) SB 562, which was passed without a funding plan, and would establish a government-run, single-payer health care system in California that will cost hundreds of billions of dollars.

Fact Sheet: What They Are Saying About Single-Payer

Fact Sheet: What They Are Saying About Single-Payer

CAHP Statement: CAHP Names New Vice President of Communications

The California Association of Health Plans (CAHP) today announced that Mary Ellen Grant has joined its staff as Vice President of Communications. She will lead communications efforts on behalf of the 49 full-service health plans CAHP represents.

Fact Sheet: Shining a Light on High-Priced Drugs

Fact Sheet: Shining a Light on High-Priced Drugs

CAHP Statement: California Senate Votes on Widely-Supported Drug Price Transparency Bill

The California State Senate Committee on Health is set to vote today on SB 17, which responds to growing concerns over the impacts of drug companies’ efforts to push the limits on prescription drug prices that have left California families and state programs grappling with the realities of six-figure price tags for common medications.

Runaway Rx: Infographic – SB 17: Transparency in Drug Pricing

Runaway Rx: Infographic - SB 17: Transparency in Drug Prici…

Runaway Rx: Bipartisan Support for Drug Price Transparency

Runaway Rx: Bipartisan Support for Drug Price Transparency

CAHP Statement: Health Plans Statement on SB 17 (Hernandez)

State Senator Ed Hernandez (D-West Covina) was joined by consumer advocates, labor representatives and other California leaders today as he introduced SB 17, which will bring much-needed transparency to prescription drug pricing. The introduction of SB 17 marks the third time in three years that California legislators have pushed to shine a light on how the pharmaceutical industry prices its products.